Article
Feasibility of a microarray-based point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity.
BioMed research international - 1 Jan 2013
Chae Hyojin, Kim Myungshin, Koh Yoon-Seok, Hwang Byung-Hee, Kang Min-Kyu, Kim Yonggoo, Park Hae-Il, Chang Kiyuk
Abstract excerpt
Clopidogrel is a prodrug which is converted into active metabolite by cytochrome P450 isoenzyme, CYP2C19. Numerous polymorphisms of CYP2C19 are reported, and a strong link exists between loss-of-function (LOF) or gain-of-function polymorphisms, clopidogrel metabolism, and clinical outcome. Hence, a fully automated point-of-care CYP2C19 genotyping assay is more likely to bring personalized antiplatelet therapy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.